Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

IPO boom: 8 biotechs bag half a billion in a banner week
Fierce Biotech
Friday, February 7, 2014 - 10:59am
tags:
IPOs, Argos Therapeutics, Eleven Biotherapeutics, Revance Therapeutics, Egalet, uniQure, Auspex Pharmaceuticals, Genocea Biosciences, Biocept
AbbVie is hit with 5 lawsuits citing the dangers of its 'low T' drug
Fierce Pharma
Friday, February 7, 2014 - 10:52am
tags:
AbbVie, Androgel, FDA
Pradaxa files show drug marketers weighing in on how to communicate the drug's risks
Fierce Pharma
Friday, February 7, 2014 - 10:50am
tags:
Pradaxa, Boehringer Ingelheim, blood thinners
[video]Biotech Losers: InterMune, Enanta, and GW Pharmaceuticals
Motley Fool
Friday, February 7, 2014 - 10:49am
tags:
InterMune, GW Pharma, Enanta
MiMedx Set For A Continued Plunge
Seeking Alpha
Friday, February 7, 2014 - 10:48am
tags:
MiMedx, devices, EpiFix
Repros Shares Soar After FDA Meeting
Yahoo/Zacks.com
Friday, February 7, 2014 - 10:37am
tags:
FDA, Repros Therapeutics, Androxal
Merck & Co., Inc. Pushing The Throttle On Oncology
Motley Fool
Friday, February 7, 2014 - 10:29am
tags:
Merck, oncology, cancer, MK-3475
Biogen Idec Inc.: Tecfidera Continues Its Blistering Pace
Motley Fool
Friday, February 7, 2014 - 9:47am
tags:
Tecfidera, Biogen Idec, MS, multiple sclerosis
A Way To Increase Drug R&D Success Rates
Forbes
Friday, February 7, 2014 - 9:46am
tags:
R&D, Accelerating Medicines Partnership
New Study Provides Good News For Intuitive Surgical
Forbes
Friday, February 7, 2014 - 9:44am
tags:
Intuitive Surgical, hysterectomies, Da Vinci Surgical System, devices
Eight Biotech Stocks Trading Near $5 With Huge Upside Potential
24/7 Wall St
Friday, February 7, 2014 - 9:43am
tags:
Array Biopharma, Biodel, Galena Biopharma, Novavax, Protalix BioTherapeutics, Rigel Pharmaceuticals, Synta Pharmaceuticals, Zogenix
Roche wins battle against India sales of generic cancer drug
FT.com
Friday, February 7, 2014 - 9:40am
tags:
Roche, India, breast cancer, biosimilars, Biocon, Mylan
Bristol-Myers Has A Bright Future Outlook
Seeking Alpha
Friday, February 7, 2014 - 9:39am
tags:
Bristol-Myers Squibb, earnings
Shire scraps Vyvanse for depression after failed trials
Yahoo/Reuters
Friday, February 7, 2014 - 9:37am
tags:
Shire, Vyvanse, ADHD, clinical depression
IPO Preview: Argos Therapeutics
Seeking Alpha
Friday, February 7, 2014 - 9:30am
tags:
IPOs, Argos Therapeutics, AGS-003, renal cell carcinoma
IPO Preview: NephroGenex
Seeking Alpha
Friday, February 7, 2014 - 9:28am
tags:
IPOs, NephroGenex, kidney disease
Neurocrine Biosciences' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Seeking Alpha
Friday, February 7, 2014 - 9:24am
tags:
Neurocrine Biosciences, earnings
AstraZeneca Boasts of Pipeline as Analysts See Deal Ahead
Bloomberg
Friday, February 7, 2014 - 9:22am
tags:
AstraZeneca, roxadustat, kidney disease, non-small cell lung cancer, AZD9291
Merck Said to Agree to $100 Million NuvaRing Settlement
Bloomberg
Thursday, February 6, 2014 - 6:13pm
tags:
Merck, Nuvaring
Medicines Co. Awarded BARDA Contract
Yahoo/Zacks.com
Thursday, February 6, 2014 - 6:12pm
tags:
BARDA, The Medicines Company, Carbavance

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.